CSS
IOBT

Cubist Systematic Strategies’s IO Biotech IOBT Stock Holding History

Cubist Systematic Strategies’s Portfolio IOBT Stock Details IOBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13,096
Closed -$18.2K – 3259
2025
Q2 		$18.2K Buy
+13,096
New +$15K ﹤0.01% 2828

Other funds holding IOBT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Cubist Systematic Strategies's IOBT Position: Q3 2025 in Review

Cubist Systematic Strategies sold out of IO Biotech (IOBT) in Q3 2025, closing a stake of 13,096 shares — an estimated $18.2K sold.

Cubist Systematic Strategies first reported a position in IOBT in Q2 2025 and held it in 1 quarter. The position peaked at $18.2K in Q2 2025. 21 funds tracked by Wall St. Rank hold IOBT as of Q3 2025.

  • Cubist Systematic Strategies reported no remaining IO Biotech position as of Q3 2025 after selling out during the quarter.
  • Cubist Systematic Strategies sold 13,096 IO Biotech shares in Q3 2025, an estimated $18.2K.
  • Cubist Systematic Strategies first reported a position in IO Biotech in Q2 2025 and held it in 1 quarter.
  • Cubist Systematic Strategies's IO Biotech position peaked at $18.2K in Q2 2025.
  • 21 funds tracked by Wall St. Rank held IO Biotech as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.